Form 4: Bolt Biotherapeutics CEO Reprices Over 100K Stock Options
Insider Transaction Report
Bolt Biotherapeutics' CEO, William P. Quinn, repriced 108,286 employee stock options, exchanging higher exercise price options for new ones at $5.44 per share.
Summary
- William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, Inc. (BOLT), engaged in a series of stock option transactions on December 12, 2025.
- These transactions involved the cancellation of previously granted employee stock options with significantly higher exercise prices.
- In exchange, new employee stock options were granted for the same number of shares, but with a uniform exercise price of $5.44 per share.
- A total of 108,286 common stock options were repriced across eight separate grants.
- The original exercise prices ranged from $7.02 to $400 per share, all replaced by options at $5.44 per share.
- Some of the new options are fully vested and exercisable, while others have vesting schedules tied to continuous service, starting from various dates between January 1, 2023, and July 15, 2024.
- The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged contract or instruction for the purchase or sale of equity securities.
Sentiment
Score: 3
Explanation: The repricing of stock options is generally a negative signal for shareholders, indicating past underperformance and potential dilution. While it aims to retain management, it often comes at the expense of shareholder value. The very low new exercise price compared to original prices highlights significant value destruction.
Positives
- The repricing provides a significantly lower exercise price for the CEO's stock options, potentially increasing their intrinsic value and incentive to remain with the company.
- The new options, particularly those with immediate vesting, offer immediate potential for profit if the stock price is above $5.44.
Negatives
- Stock option repricing typically occurs when the company's stock price has fallen significantly below previous grant prices, indicating past underperformance.
- Repricing can be viewed negatively by shareholders as it effectively 'resets' executive compensation at a lower bar, potentially diluting shareholder value and signaling a lack of accountability for prior stock performance.
- The substantial reduction in exercise prices (e.g., from $400 to $5.44) highlights a significant decline in the company's stock value since the original grant dates.
Future Outlook
The filing does not provide explicit forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedules for the repriced options.
Industry Context
Stock option repricing is a practice sometimes employed by companies, particularly in volatile sectors like biotechnology, when their stock price has significantly declined. It aims to restore the incentive value of options for key executives and retain talent, especially when original grant prices are far 'out of the money.' However, it often signals past underperformance relative to the market or peers.
Comparison to Industry Standards
- Repricing of executive stock options is generally viewed unfavorably by corporate governance advocates and institutional investors, as it can be perceived as rewarding management despite poor stock performance.
- While not uncommon in certain circumstances, particularly in biotech where stock valuations can be highly sensitive to clinical trial results and market sentiment, it typically raises questions about executive accountability and alignment with shareholder interests.
- Specific comparable companies or projects are not mentioned in the filing to allow for direct comparison of results.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Adjustment | The company approved the cancellation of existing employee stock options and the grant of new options with a lower exercise price for its President, CEO, and CFO, William P. Quinn. This action was taken under a Rule 10b5-1(c) plan. | 2025-12-12 | This repricing event impacts executive compensation structure, potentially improving executive retention and motivation by restoring the incentive value of options. However, it may raise corporate governance concerns regarding shareholder alignment and accountability for past stock performance. |
Stakeholder Impact
- Shareholders: Potential negative impact due to perceived dilution and the signal of past underperformance. May raise concerns about executive accountability.
- Employees (specifically the CEO): Positive impact through restored incentive value of stock options, potentially enhancing retention and motivation.
Next Steps
- The repriced options will continue to vest according to their respective schedules, with some already fully vested and others vesting monthly over 36 months from various dates.
Key Dates
| Date | Description |
|---|---|
| 2020-07-29 | Original grant date for 7,614 options (cancelled). |
| 2020-09-03 | Original grant date for 3,927 options (cancelled). |
| 2021-02-04 | Original grant date for 5,000 options (cancelled). |
| 2022-02-18 | Original grant date for 10,499 options (cancelled). |
| 2023-01-01 | Vesting commencement date for 12,499 repriced options (1/36th per month). |
| 2023-02-27 | Original grant date for 12,499 options (cancelled). |
| 2024-01-01 | Vesting commencement date for 11,749 repriced options (1/36th per month). |
| 2024-03-04 | Original grant date for 11,749 options (cancelled). |
| 2024-07-15 | Vesting commencement date for 21,999 repriced options (1/36th per month). |
| 2024-07-23 | Original grant date for 21,999 options (cancelled). |
| 2025-01-01 | Vesting commencement date for 34,999 repriced options (1/36th per month). |
| 2025-05-01 | Original grant date for 34,999 options (cancelled). |
| 2025-12-12 | Date of all reported option repricing transactions. |
| 2025-12-16 | Signature date of the reporting person for the filing. |
| 2030-07-28 | Expiration date for 7,614 repriced options. |
| 2030-09-02 | Expiration date for 3,927 repriced options. |
| 2031-02-03 | Expiration date for 5,000 repriced options. |
| 2032-02-17 | Expiration date for 10,499 repriced options. |
| 2033-02-26 | Expiration date for 12,499 repriced options. |
| 2034-03-03 | Expiration date for 11,749 repriced options. |
| 2034-07-22 | Expiration date for 21,999 repriced options. |
| 2035-04-30 | Expiration date for 34,999 repriced options. |
Recommendation
holdThe repricing of executive stock options typically indicates significant past underperformance of the company's stock, which is a negative signal. While it aims to retain key management, it can be viewed unfavorably by investors. Without additional financial or operational updates, a 'hold' recommendation is appropriate, acknowledging the negative implications of repricing while recognizing the company's effort to maintain executive incentives.
Keywords
Bolt Biotherapeutics, BOLT, Stock Options, Repricing, Executive Compensation, Form 4, Insider Transaction, William P. Quinn, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.